SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    David M. Roy, Logan A. Walsh, Timothy A. Chan, Driver mutations of cancer epigenomes, Protein & Cell, 2014, 5, 4, 265

    CrossRef

  2. 2
    Laura Zaldumbide, Asier Erramuzpe, Rosa Guarch, Jesús M. Cortés, José I. López, Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous, Virchows Archiv, 2014,

    CrossRef

  3. 3
    J. Michael Randall, Frederick Millard, Razelle Kurzrock, Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art, Cancer and Metastasis Reviews, 2014,

    CrossRef

  4. 4
    Srikanth Kudithipudi, Denis Kusevic, Albert Jeltsch, Non-radioactive Protein Lysine Methyltransferase Microplate Assay Based on Reading Domains, ChemMedChem, 2014, 9, 3
  5. 5
    Jaclyn A. Biegel, Tracy M. Busse, Bernard E. Weissman, SWI/SNF chromatin remodeling complexes and cancer, American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2014, 166, 3
  6. 6
    Ilsiya Ibragimova, Marie E. Maradeo, Essel Dulaimi, Paul Cairns, Aberrant promoter hypermethylation ofPBRM1,BAP1,SETD2,KDM6Aand other chromatin-modifying genes is absent or rare in clear cell RCC, Epigenetics, 2013, 8, 5, 486

    CrossRef

  7. 7
    Berton Zbar, From Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes: A Personal History, Colloquium Series on The Genetic Basis of Human Disease, 2013, 2, 1, 1

    CrossRef

  8. 8
    Małgorzata Rydzanicz, Tomasz Wrzesiński, Hans A.R. Bluyssen, Joanna Wesoły, Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications, Cancer Letters, 2013, 341, 2, 111

    CrossRef

  9. 9
    Swathi Ramakrishnan, Roberto Pili, Histone Deacetylase Inhibitors and Epigenetic Modifications as a Novel Strategy in Renal Cell Carcinoma, The Cancer Journal, 2013, 19, 4, 333

    CrossRef

  10. 10
    Rafal Pawłowski, Sarah M. Mühl, Tullio Sulser, Wilhelm Krek, Holger Moch, Peter Schraml, Loss of PBRM1 expression is associated with renal cell carcinoma progression, International Journal of Cancer, 2013, 132, 2
  11. 11
    Sunil Sudarshan, Jose A. Karam, James Brugarolas, R. Houston Thompson, Robert Uzzo, Brian Rini, Vitaly Margulis, Jean-Jacques Patard, Bernard Escudier, W. Marston Linehan, Metabolism of Kidney Cancer: From the Lab to Clinical Practice, European Urology, 2013, 63, 2, 244

    CrossRef

  12. 12
    Christopher J Ricketts, Mark R Morris, Dean Gentle, Salwati Shuib, Michael Brown, Noel Clarke, Wenbin Wei, Paul Nathan, Farida Latif, Eamonn R Maher, Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma, Clinical Epigenetics, 2013, 5, 1, 16

    CrossRef

  13. 13
    James Brugarolas, PBRM1 and BAP1 as Novel Targets for Renal Cell Carcinoma, The Cancer Journal, 2013, 19, 4, 324

    CrossRef

  14. 14
    Rachel A. Craven, Naveen S. Vasudev, Rosamonde E. Banks, Proteomics and the search for biomarkers for renal cancer, Clinical Biochemistry, 2013, 46, 6, 456

    CrossRef

  15. 15
    Ryan S. Lee, Charles W. M. Roberts, Rhabdoid Tumors: An Initial Clue to the Role of Chromatin Remodeling in Cancer, Brain Pathology, 2013, 23, 2
  16. 16
    Gerben Duns, Anke van den Berg, Marcory C. R. F. van Dijk, Inge van Duivenbode, Cor Giezen, Joost Kluiver, Harry van Goor, Robert M. W. Hofstra, Eva van den Berg, Klaas Kok, The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney, Genes, Chromosomes and Cancer, 2013, 52, 2
  17. 17
    Rajmohan Murali, Thomas Wiesner, Richard A. Scolyer, Tumours associated with BAP1 mutations, Pathology, 2013, 45, 2, 116

    CrossRef